University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
Saint Luke's Hospital of Kansas City, Kansas City, MO, USA.
Int J Artif Organs. 2024 Apr;47(4):309-312. doi: 10.1177/03913988241239198. Epub 2024 Mar 20.
Our study aimed to compare the outcomes of COVID-19 patients who met a low-risk inclusion criteria for veno-venous extra corporeal membrane oxygenation (VV ECMO) with those who did not meet criteria due to higher risk but were subsequently cannulated.
This was a retrospective observational cohort study that included adult patients who were placed on VV ECMO for COVID-19 related acute respiratory distress syndrome (ARDS) at a tertiary care academic medical center. The primary outcome was the association between the low-risk criteria and mortality. The patients met the criteria if they met EOLIA severe ARDS criteria, no absolute contraindications (age > 60 years, BMI > 55 kg/m, mechanical ventilation (MV) duration >7 days, irreversible neurologic damage, chronic lung disease, active malignancy, or advanced multiorgan dysfunction), and had three or less relative contraindications (age > 50 years, BMI > 45 kg/m, comorbidities, MV duration > 4 days, acute kidney injury, receiving vasopressors, hospital LOS > 14 days, or COVID-19 diagnosis > 4 weeks).
Sixty-five patients were included from March 2020 through March 2022. Patients were stratified into low-risk or high-risk categories. The median Sequential Organ Failure Assessment score was 7 and the median PaO2/FiO2 ratio was 44 at the time of ECMO cannulation. The in-hospital mortality was 47.8% in the low-risk group and 69.0% in the high-risk group ( = 0.096).
There was not a statistically significant difference in survival between low-risk patients and high-risk patients; however, there was a trend toward higher survival in the lower-risk group.
本研究旨在比较符合低危纳入标准行静脉-静脉体外膜肺氧合(VV ECMO)的 COVID-19 患者与因高危但随后行置管的患者的结局。
这是一项回顾性观察性队列研究,纳入在三级学术医疗中心因 COVID-19 相关急性呼吸窘迫综合征(ARDS)行 VV ECMO 的成年患者。主要结局为低危标准与死亡率之间的关系。患者符合标准的条件为符合 EOLIA 严重 ARDS 标准、无绝对禁忌证(年龄>60 岁、BMI>55kg/m、机械通气(MV)时间>7 天、不可逆性神经损伤、慢性肺部疾病、活动性恶性肿瘤或晚期多器官功能障碍),且存在 3 项或更少的相对禁忌证(年龄>50 岁、BMI>45kg/m、合并症、MV 时间>4 天、急性肾损伤、使用血管加压药、住院时间>14 天或 COVID-19 诊断>4 周)。
纳入 2020 年 3 月至 2022 年 3 月的 65 例患者。患者分为低危或高危组。ECMO 置管时序贯器官衰竭评估(SOFA)评分中位数为 7 分,动脉血氧分压/吸入氧浓度(PaO2/FiO2)比值中位数为 44。低危组院内死亡率为 47.8%,高危组为 69.0%(=0.096)。
低危患者与高危患者的存活率无统计学差异;但低危组的存活率有升高趋势。